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ABSTRACT 
Background: Despite positive outcomes of transcutaneous vagus nerve stimulation 
(tVNS) via the auricular branch of the vagus nerve (ABVN), the mechanisms 
underlying these outcomes remain unclear. Additionally, previous studies have not been 
controlled the possible placebo effects of tVNS.  
Objective: To test the hypothesis that tVNS acutely improves spontaneous cardiac 
baroreflex sensitivity (cBRS) and autonomic modulation, and that these effects are 
specific to stimulation of ABVN. 
Methods: Thirteen healthy men (23±1yrs) were randomized across three experimental 
visits. In active tVNS, electrodes were placed on the tragus of the ear and electrical 
current was applied by using a Transcutaneous Electrical Nerve Stimulation device. A 
time-control visit was performed with the electrodes placed on tragus, but no current 
was applied (sham-T). Additionally, to avoid a placebo effect, another sham protocol 
was performed with same electrical current of the active visit, but the electrodes were 
placed on the ear lobe (an area without cutaneous nerve endings from the vagus – tLS). 
Beat-to-beat heart rate (HR) and blood pressure (BP) were monitored at rest, during 
stimulation (active, sham-T and tLS) and recovery. cBRS was measured via sequence 
technique. Both HR (HRV) and BP variability (BPV) were also measured. 
Results: Arterial BP and BPV were not affected by any active or sham protocols 
(P>0.05). Resting HR and LF/HF ratio of HRV decreased (∆–3.4±1% and ∆–15±12%, 
P<0.05, respectively) and cBRS increased (∆24±8%, P<0.05) during active tVNS, but 
were unchanged during both sham protocols.  
Conclusion: tVNS acutely improves cBRS and autonomic modulation in healthy young 
men. 
 
Key-words: baroreflex; autonomic nervous system; sympathetic nervous system; 
neuromodulation. 
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INTRODUCTION 
It is well established that some diseases are accompanied by severe cardiac 
autonomic dysfunction characterized by sustained excessive sympathetic outflow and 
parasympathetic withdrawal (e.g. hypertension, diabetes, heart failure, coronary artery 
disease, obesity) [1-4]. Given the significant financial costs associated with the 
development of novel pharmaceutical drugs, there is increasing interest in non-
pharmacological alternatives. 
Electrical vagus nerve stimulation (VNS) has been approved for use in 
treatment-resistant patients with epilepsy and major depressive disorder and has been 
further suggested as a potential treatment for a broad range of conditions including 
Alzheimer’s disease, heart failure, inflammation, chronic pain, diabetes, tinnitus and 
obesity [5-12]. However, VNS requires an invasive surgical procedure for electrode 
implantation and has been associated with adverse side-effects such as dysphonia, vocal 
hoarseness and dyspnea [13, 14]. As such, this limits the application of VNS to patients 
who are treatment-resistant to all existing pharmacological approaches. Given these 
considerations, non-invasive transcutaneous vagus nerve stimulation (tVNS) via the 
auricular branch of the vagus nerve (ABVN) has been developed, with similar efficacy 
to the invasive technique [15] and beneficial outcomes for patients with epilepsy [16, 
17], coronary artery disease [18] and major depressive disorder [19]. 
The physiological mechanisms behind VNS-induced changes in cardiovascular 
function have been investigated over the past few years. An underlying mechanism that 
may explain the improvements in autonomic function by VNS is the increase in arterial 
baroreflex sensitivity. In this context, a recent study demonstrated that invasive VNS 
resets the baroreflex function and induces sympathoinhibition in rats [20]. However, the 
effect of VNS on arterial baroreflex sensitivity in humans requires further investigation. 
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Clancy et al. [21] demonstrated in humans that tVNS acutely improved cardiac 
autonomic modulation assessed by heart rate (HR) variability (HRV), likely to be at 
least in part due to a reduction in sympathetic nerve activity measured with 
microneurography. More recently, De Couck et al. [22] verified that short (10-min) and 
long term (60-min) tVNS slightly improves HRV in healthy subjects. Unfortunately, 
these previous studies did not measure spontaneous cardiac baroreflex sensitivity 
(cBRS). 
Additionally, both Clancy et al. [21] and De Couck et al. [22] compared active 
tVNS (electrical current applied on ABVN) with control protocol (electrodes placed on 
the ABVN but no current was applied). Such approach can possibly bias the 
interpretation about the tVNS effect, because tVNS induces nuisance, which not occurs 
during the control protocol. In this sense, the subject’s expectancy about the 
intervention becomes unpredictable, such that subjects may think the tVNS is either 
beneficial (i.e., placebo) or harmful (i.e., nocebo). Placebo and nocebo effects, in turn, 
could per se influence autonomic regulation [23]. In this context, a possible approach to 
avoid the placebo effects of tVNS is to mimic the same electrical stimulation, but 
applying the current on an auricular site that is not innervated by the ABVN, such as the 
ear lobe [24]. 
On the basis of these considerations, the present study was designed to test the 
hypothesis that acute non-invasive VNS through the ABVN would improve 
spontaneous cBRS, HRV and blood pressure (BP) variability (BPV) in healthy young 
male subjects. It further tested whether these effects were specific to stimulation of 
auricular regions innervated by the ABVN or is partially placebo-mediated. 
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METHODS 
Subjects 
Young male subjects (n = 13; age = 23 ± 1 yrs) participated in the present 
study with mean weight and height of, 80 ± 3 kg; 177 ± 2 cm (mean ± SEM), 
respectively. The rationale for including only men are based on the fact the 
cardiovascular control is markedly different between men and women [25]. In addition, 
the cyclical variations in female sex hormones across the menstrual cycle (i.e., estrogen 
and progesterone) could be a confound factor [26, 27]. All subjects were healthy, 
normotensive, non-smokers, and were recreationally active (self-reported habitual 
physical activity for at least 6 consecutive months with a minimum frequency of 3 days 
per week in ≥ 30-min sessions). Subjects had no history or symptoms of cardiovascular, 
pulmonary, metabolic, or neurological disease as determined from a detailed medical 
health history questionnaire. No subjects were using prescribed or over-the-counter 
medications. Participants were recruited through posters placed at the University of 
Brasília, Brazil. Written informed consent was obtained from all subjects and all study 
procedures were approved by the University of Brasília institutional research committee 
(CAAE: 54104216.0.0000.0030) in accordance with the Declaration of Helsinki. 
 
Study Protocol 
The study was randomized, placebo-controlled, and crossed-over. Subjects 
performed four visits to the laboratory. In the visit one, the participants’ body weight 
and height were assessed, and a familiarization session of tVNS was performed. Then, 
on visits two, three and four the subjects were exposed in a random order to : 1) active 
tVNS 2) sham, where electrodes were placed on the tragus of the ear but no current was 
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applied (sham tragus – sham-T), and 3) electrodes were placed on the ear lobe and 
current applied according with active tVNS (transcutaneous lobe stimulation – tLS). 
Participants were seated (90° of knee angle) while HR, finger arterial BP and respiration 
were monitored continuously. Data recordings were obtained at baseline (10 minutes), 
during test period (15 minutes; active tVNS, sham-T or tLS), and during recovery (10 
minutes). 
HR and arterial BP were measured on a continuous beat-to-beat basis using 
finger photoplethysmography (Human NIBP Controller, AD instruments, NSW, 
Australia). Brachial arterial BP was also measured with an automated digital 
sphygmomanometer (Omron, HEM-7200, Japan) for absolute measures of BP and to 
confirm finger measurements. Respiratory frequency was visually monitored in order to 
avoid the potential confounding influence of large respiratory excursions on 
cardiovascular measurements. 
The subjects were asked to refrain from consuming caffeine/alcohol and from 
engaging in physical exercise for 6 and 24 h, respectively, prior to the tests. To avoid 
potential diurnal variations, subjects were always tested at the same time of day for each 
subject and in the same quiet, temperature-controlled room (~21°C). 
 
Transcutaneous vagus nerve stimulation (tVNS) 
Figure 1 shows the experimental design of the present study. The ABVN 
innervates the skin of parts of the ear (i.e. concha, tragus and cymba concha) and the ear 
lobe has no nerve endings of the vagus nerve (Fig. 1A). The transcutaneous electrical 
nerve stimulation (TENS) device consisted of a small stimulation unit (V-TENS Plus, 
Body Clock Health Care Ltd, UK) and modified surface electrodes bilaterally placed on 
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the inner and outer surface of the tragus of the ear during active and sham-T protocols  
(Fig. 1B), and on the ear lobe during tLS protocol (Fig. 1C). The active tVNS protocol 
was performed according with previous reports [15, 21, 28]. Briefly, the electrical 
current was applied continuously for 15 min with a pulse width of 200 µs and pulse 
frequency of 30 Hz. The stimulation amplitude was adjusted between 10 and 50 mA, at 
level of each participant’s sensory threshold. In the sham-T protocol, the electrode was 
attached to the tragus and the amplitude was increased until the participant reported 
sensation. Participants were then told that stimulation interventions would be equivalent 
types of “nerve stimulation”, though they might perceive them differently but the 
electrode leads were disconnected from the TENS machine without the participants’ 
knowledge. During the tLS protocol, the electrode was placed on the ear lobe and the 
electrical current was applied with the same parameters as the active tVNS. The tLS 
protocol was performed to exclude the possibility of any confounding sensory effect of 
tVNS due to electrodes being sited at the ABVN dermatome, and to determine if the 
effects of stimulation were specific to the tragus and not due to the sensation of 
stimulus. 
 
Spontaneous cardiac baroreflex sensitivity (cBRS) 
Beat-to-beat time series of systolic BP and RR intervals were analyzed using 
the sequence technique for estimating spontaneous cBRS (CardioSeries v2.4, Brazil). 
The sequence technique is based on the identification of sequences of consecutive beats 
in which progressive increases in systolic BP are followed by a progressive lengthening 
in RR interval or vice versa; progressive decreases in systolic BP are followed by a 
progressive shortening in RR interval [29]. Briefly, sequences of three or more 
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consecutive beats with corresponding increases or decreases in systolic BP and RR 
interval were identified as arterial baroreflex sequences (GAINall). Sequences were 
detected only when the variation in RR interval was greater than 1.0 ms, systolic BP 
changes were greater than 1 mmHg, and ≥3 consecutive cardiac cycles. A linear 
regression was applied to each individual sequence and only those sequences in which 
R2 was >0.85 were accepted. The slopes of the systolic BP and RR interval relationships 
were then calculated and averaged for a measure of spontaneous cBRS. Overall results 
were similar when HR was used as the dependent variable for these cBRS measures and 
therefore only RR interval measures are presented. In addition, the gains for up 
(GAINup) and down (GAINdown) sequences and the total number of sequences detected 
were also calculated. 
 
 
Heart rate variability (HRV) 
HRV was determined in accordance with the guidelines of the Task Force of 
the European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology [30]. A continuous recording of a single lead ECG, usually CC5 or 
CM5, was obtained continuously during the test. Variables were sampled at 1000 Hz 
and stored for offline analysis (CardioSeries v2.4, Brazil). Only segments without signal 
noise were analyzed. All ectopic beats on the ECG trace were identified both 
automatically and manually before exclusion from the analysis. A fast Fourier 
transformation (512 points) was used for spectral analysis of HRV. The power spectra 
were quantified by measuring the area under the following frequency bands: very low 
frequency power (VLF) (< 0.04Hz), low-frequency power (LF) (0.04–0.15 Hz) and 
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high-frequency power (HF) (0.15–0.4 Hz). As no firm evidence has yet been presented 
for the physiological meaning of the VLF band, only the power densities of LF and HF 
band were investigated. Total power and normalized units of LF and HF were also 
calculated. Normalized units were calculated by dividing each spectral band by the total 
power minus the VLF power and were multiplied by 100. The ratio of LF to HF 
(LF/HF) was also calculated as a measure of autonomic balance. 
 
Blood pressure variability (BPV) 
Spectral analysis of BPV was performed employing the software CardioSeries 
v2.4, which uses Fourier transformation to calculate spectral power of HRV and systolic 
BPV. BPV was calculated after appropriate spline interpolation and equidistant 
representation of systolic BP data. The VLF band was defined in the range of 0.02–0.07 
Hz, the LF band in the area of 0.07–0.15 Hz, and the HF band between 0.15 and 0.40 
Hz [31]. The LF component of BPV was used as a proxy of the sympathetic modulation 
of the vascular tone [31].  
 
Statistical analysis 
Shapiro-Wilk normality test was used to verify the normal distribution of the 
data. As the majority of the data presents a non-normal distribution, non-parametric 
statistical tests were applied. To analyze the effects of active, control and sham 
interventions, the baseline, tVNS and recovery recordings were compared using 
Friedman’s analysis of variance (ANOVA), followed by Wilcoxon signed-rank paired 
test with Bonferroni correction to detect the difference in pairwise comparisons. All 
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data are presented as mean ± SEM. The figures are expressed as percentage of delta. 
The level of significance accepted for main effects was P < 0.05 and for post-hoc 
pairwise comparisons was P < 0.017. Statistical analyses were conducted using the 
software STATISTICA (Statsoft, USA). 
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RESULTS 
 
Baseline characteristics of the subjects are present in Table 1. No significant 
differences are found in any resting physiological variables between active, sham-T and 
tLS protocols (P > 0.05). During both active tVNS and tLS, the range of the stimulation 
amplitude was between 40-50 mA, with an average of 45 ± 1 mA.  
Active tVNS significantly increased cBRS GAINall (baseline: 12.7 ± 1 
ms/mmHg; tVNS: 15.1 ± 1 ms/mmHg; recove/ry: 13.1 ± 1 ms/mmHg; Interaction P = 
0.04, Fig. 2A black square) (∆24 ± 8%, active tVNS vs. baseline; P = 0.0159). In 
striking contrast,  no changes were observed during sham-T (baseline: 13.1 ± 1 
ms/mmHg; sham-T tVNS: 13.7 ± 1 ms/mmHg; recovery: 13.4 ± 1 ms/mmHg; 
Interaction P = 0.73, Fig. 2A white circles) (∆6 ± 5%, sham-T vs. baseline) or tLS 
(baseline: 13.6 ± 1 ms/mmHg; tLS: 13.9 ± 1 ms/mmHg; recovery: 13.8 ± 1 ms/mmHg; 
Interaction P = 0.23, Fig. 2A gray triangles) (∆3 ± 2%, tLS vs. baseline) protocols. 
Similarly, the gains for up (Fig. 2B) and down (Fig. 2C) sequences significantly 
increased during active tVNS (GAINup: ∆24 ± 11% vs. rest, P = 0.014; GAINdown: ∆26 
± 7% vs. rest, P = 0.003), but was unchanged during either sham-T (GAINup: ∆8 ± 6% 
vs. rest, P = 0.202; GAINdown: ∆4 ± 5% vs. rest, P = 0.257) and tLS (GAINup: ∆-2 ± 3% 
vs. rest, P = 0.336; GAINdown: ∆7 ± 4% vs. rest, P = 0.072). The total number of 
sequences was not significantly different between active tVNS, sham-T or tLS (125 ± 
12 vs. 125 ± 11 vs. 122 ± 14 respectively, P = 0.93). 
 
Active tVNS slightly but significantly reduces HR before return to baseline 
values during recovery period (baseline: 72 ± 3 bpm; active tVNS: 69 ± 2 bpm; 
recovery: 71 ± 2 bpm; Interaction P = 0.02, Fig. 3A black squares) (∆–3.4 ± 1% active 
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tVNS vs. baseline; P = 0.004). However, HR was unchanged during sham-T (baseline: 
73 ± 2 bpm; sham-T: 71 ± 1 bpm; recovery: 73 ± 1 bpm; Interaction P = 0.07, Fig. 3A 
white circles) (∆–1.5± 1% sham-T vs. baseline) or tLS (baseline: 73 ± 2 bpm; tLS: 73 ± 
2 bpm; recovery: 73 ± 3 bpm; Interaction P = 0.38, Fig. 3A gray triangles) (∆–1.2 ± 1% 
tLS vs. baseline). Systolic BP was unchanged by either active, sham-T or tLS protocols 
(P > 0.05, Fig. 3B). 
 
Consistent with previous publications, active tVNS significantly reduced 
LF/HF ratio, an index of sympathovagally-mediated oscillations in HR variability, and 
returned to baseline values during recovery (baseline: 2.0 ± 0.3; active tVNS: 1.53 ± 
0.3; recovery: 2.43 ± 0.5; Interaction P = 0.02, Fig. 3C black squares) (∆–15 ± 12%, 
active tVNS vs. baseline; P = 0.014). On the other hand, no changes in LF/HF ratio 
were observed in either sham-T (baseline: 2.3 ± 0.4; sham-T: 2.65 ± 0.5; recovery: 2.87 
± 0.4; Interaction P = 0.50, Fig. 3C white circles) (∆23 ± 16%, sham-T vs. baseline) or 
tLS (baseline: 1.72 ± 0.2; tLS: 1.65 ± 0.2; recovery: 2.1 ± 0.3; Interaction P = 0.23, Fig. 
3C gray triangles) (∆4 ± 10%, tLS vs. baseline) protocols. Interesting, both absolute 
(ms2) and normalized (nu) values for LF and HF components of HRV were unchanged 
during any conditions with exception of LF (ms2) which significantly increased during 
sham-T (∆48 ± 15%, vs. rest, P = 0.002) and trend to increase during tLS (∆29 ± 13%, 
vs. rest, P = 0.023), but was unchanged during active tVNS (∆4 ± 11%, vs. rest). 
Importantly, the respiration rate was unchanged during any of the conditions. 
No differences were found in LF power of SBP variability,  during any active 
(∆–8 ± 10% active tVNS vs. baseline; Interaction P = 0.56, Fig. 3D black squares), 
sham-T (∆37 ± 13%, sham-T vs. baseline; Interaction P = 0.80, Fig. 3D white circles) 
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and tLS (∆29 ± 16%, tLS vs. baseline; Interaction P = 0.79, Fig. 3D grey triangles) 
protocols 
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DISCUSSION 
In accordance with our initial hypothesis, the present study shows that: 1) 
active tVNS acutely improves spontaneous cBRS; 2) LF/HF ratio is decreased by tVNS 
in healthy young men; 3) tVNS evokes slight decrease in HR; and 4) the 
aforementioned effects are specific to stimulation of ABVN.  
A major finding of this study is that spontaneous cBRS increased in response 
to tVNS of the ABVN. The baroreflex is a closed-loop, negative feedback control 
system that constantly senses arterial pressure by baroreceptors in a beat-to-beat fashion 
and quickly regulates systemic arterial pressure physiologically to attenuate 
perturbations in arterial pressure [32]. Previous studies demonstrate that afferent VNS 
resets the baroreflex operating point and induces sympathoinhibition in animal models 
[20, 33]. A striking outcome of the current study was that increases in BRS were 
evident even with non-invasive VNS. Further these effects were observable even in 
healthy young men, who would be expected to have a strong baseline cBRS. Since BRS 
decreases with disease [34] and age [35], this suggests that tVNS could provide a 
significant opportunity to improve BRS in an inexpensive and non-invasive approach 
that could be generally applicable. 
This current study provides evidence supporting the view that the autonomic 
effects of auricular stimulation are mediate by the ABVN. Circumventing the possible 
sensory effects with stimulation at the earlobe, a non-ABVN innervated region, has no 
effect on reflex control of BP. This is consistent with the functional magnetic resonance 
imaging study by Frangos et al. [36] that electrical stimulation of the ear lobe did not 
activate the nucleus tractus solitarius (NTS) in the brainstem, whereas that of the 
ABVN-innervated cymba concha did. Therefore, we can attribute that the positive 
effects on reflex control of BP are due the active stimulation of ABVN per se. The 
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precise mechanisms underlying the main findings of the present study are not fully 
understood, but some relevant points should be considered.  
The central circuitry associated with tVNS autonomic effects might involve 
activation of the NTS by ABVN afferents. Since the baroreceptor afferent fibers join 
their respective glossopharyngeal nerve and also project to the NTS, tVNS might 
potentiate the effectiveness of cBRS at the NTS level [15], again consistent with 
activation of NTS by tVNS [36]. In addition, this could activate the caudal ventrolateral 
medulla to inhibit the rostral ventrolateral medulla and thus reduce sympathetic output 
to both the heart and peripheral vasculature [15, 37]. Furthermore, the NTS could also 
activate the dorsal motor nucleus of the vagus and the nucleus ambiguus to increase 
cardiac parasympathetic activity [38]. In support of this idea, Clancy et al. [21] 
demonstrated a significant attenuation in muscle sympathetic nerve activity evoked by 
tVNS, which may attenuate α-adrenergic receptors constrictor function in blood vessels 
and thus decrease peripheral vascular resistance. Considering our findings, the 
aforementioned physiological responses can be responsible for the small decreases in 
HR, the increases in cardiac autonomic modulation and spontaneous cBRS observed 
during active tVNS. 
The decreases in HR and LF/HF ratio during active tVNS are in accordance 
with the results of Clancy et al. [21], demonstrating that tVNS improves the 
sympathovagal balance, but extends it to show that tVNS was effective even in this 
sample of young males. Interestingly, the baseline LF/HF ratio was higher in our 
subjects when compared to their study [21], which may be attributed to the different 
sample sizes. Our study was performed only in young men and Clancy et al. [21] 
studied both sexes and previous studies have demonstrated that female sex hormones, 
more specifically estrogen [39], have an effect on cardiac autonomic modulation [40]. 
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In this sense, men tend to have a higher baseline LF/HF than women [41]. The reasons 
of these discrepancies are unclear, but some aspects should be considered. For example, 
it has been shown that body posture may change the autonomic and hemodynamic 
control [42, 43], and our subjects were seated while Clancy et al. [21] performed tests in 
a semi-supine position. We decided to perform experiments in a seated position due the 
fact that it is likely possible that people will conduct tVNS whilst watching TV or other 
such daily activity (i.e., external validity). In addition, our subjects were healthy, young 
and male, and the sample of Clancy et al. [21] was composed by both male and female 
subjects with a range of age between 20 to 62 years. Furthermore, the present study 
added a sham protocol that minimizes the sensory effects of tVNS (i.e., tLS) which was 
not performed by the Clancy study. 
 
Limitations 
The present study has several limitations. First, the small sample size increases 
the risk of type II error. Second, since we tested only healthy young male subjects, it is 
not possible to extrapolate the results for other populations such as female, older and/or 
diseased subjects. Future studies are necessary to examine the impact of tVNS on neural 
control of BP in these populations. Third, we used a non-perturbational spontaneous 
method to assess the arterial baroreflex sensitivity. Perturbational methods, such as 
vasoactive drugs infusion (i.e. modified Oxford), allow the examination of a prevailing 
range of pressure, while non-perturbational spontaneous method assesses a limited 
range of pressure for the stimulus-response baroreflex relationship. The results of the 
present study, however, show that sequence method was able to confirm our initial 
hypothesis. In addition, several clinical studies have used the sequence technique and 
previous authors have reported high reproducibility of spontaneous baroreflex 
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sensitivity using the sequence technique at rest and during perturbations [44-46], and 
the sequence method has been shown to correlate with the Oxford technique [47]. 
 
Perspectives 
The improvements in cBRS and sympathovagal balance caused by tVNS have 
clinical implications. Several cardiovascular disease states are accompanied by 
autonomic dysfunction, characterized by an impairment in cardiac baroreflex 
sensitivity, increased sympathetic nerve activity and parasympathetic withdrawal (e.g. 
hypertension, coronary artery disease, heart failure, diabetes and obesity) [1, 3, 4, 20]. 
In addition, cardiac autonomic dysfunction is a powerful predictor of mortality in 
patients with cardiac disease [48, 49], and in older people with low cardiovascular risk 
[50]. 
In this regard, non-pharmacological approaches (i. e., exercise and diet 
regimens) have been consistently shown to improve cBRS and autonomic modulation 
[51-53]. More recently, a promising strategy to promote beneficial outcomes for a range 
of conditions is the electrical stimulation of vagus nerve. Although VNS has been 
suggested for potential complementary treatment of a broad range of conditions 
including epilepsy, depression, Alzheimer’s disease, heart failure, inflammation, 
chronic pain, diabetes, tinnitus and obesity [5-12], the mechanisms involved in the 
efficacy of this technique remain unclear. 
 
Conclusions 
The results of the present study provide evidence that non-invasive VNS 
through the ABVN improves cBRS and autonomic modulation in healthy young male 
subjects. These findings allow us to suggest that spontaneous cBRS and cardiac 
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sympathovagal balance could play a role in the mechanisms involved in previously 
reported beneficial outcomes caused by tVNS. Future studies are needed to confirm 
these findings in older and diseased populations. 
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Figure Legends 
 
Figure 1. Experimental protocol of the study. A. The shaded area shows the distribution 
of the auricular branch of the vagus nerve to the external ear. B. Position of the 
electrodes which were placed on the tragus of the ear during active and sham-T 
protocols. C. Position of the electrodes which were placed on the ear lobe during tLS 
protocol. 
 
Figure 2. Response of cardiac baroreflex sensitivity for all (GAINall, panel A), up 
(GAINup, panel B) and down (GAINdown, panel C) sequences during the baseline, tVNS 
and recovery in the active (black squares), sham-T (white circles) and tLS (grey 
triangles) protocols. All values are mean ± SE. *P < 0.05 tVNS vs. baseline in the 
active protocol.  
 
Figure 3. Response of heart rate (HR, panel A), systolic blood pressure (SBP, panel B), 
sympathovagal balance, represented by the ratio between the low and high frequency 
components of heart rate variability (LF/HF, panel C), and low frequency component of 
systolic blood pressure variability (LFSBP, panel D) during the baseline, tVNS and 
recovery in the active (black squares), sham-T (white circles) and tLS (grey triangles) 
protocols. Values are mean ± SE. *P < 0.05 tVNS vs. baseline in the active protocol. †P 
< 0.05 tVNS vs. recovery in active  protocol. ‡P < 0.05 tVNS vs. recovery in tLS 
protocol. 
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Table 
 
Table 1. Baseline characteristics. 
 
Values are means ± SE. BMI, body mass index; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; LF/HF, ratio 
between low and high frequency powers of heart rate variability; BP, blood pressure; 
LFSBP, low frequency component of systolic blood pressure variability; P, level of 
significance (P < 0.05). 
 
Active Sham-T tLS P
Anthropometrics
Age, years 22.6 ± 1 - - -
Weight, kg 79.6 ± 3 - - -
Height, cm 177 ± 2 - - -
BMI, kg/m² 25.4 ± 1 - - -
Hemodynamics
SBP, mmHg 111 ± 1 113 ± 2 112 ± 2 0.15
DBP, mmHg 63 ± 1 63 ± 1 63 ± 2 0.71
MAP, mmHg 78 ± 1 79 ± 1 79 ± 2 0.49
HR, beats/min 72 ± 3 73 ± 2 73 ± 2 0.27
Cardiac baroreflex function
GAINall, ms/mmHg 12.7 ± 1 13.1 ± 1 13.6 ± 1 0.37
GAINup, ms/mmHg 12.7 ± 1 13.4 ± 1 14.1 ± 1 0.37
GAINdown, ms/mmHg 12.5 ± 1 13.1 ± 1 13.1 ± 1 0.37
HR variability
LF, ms2 1320.6 ± 132.0 1360.1 ± 206.8 1035.9 ± 124.9 0.23
HF, ms2 1038.8 ± 156.2 916.9 ± 161.7 752.4 ± 78.9 0.37
LF, nu 52.8 ± 4.5 57.7 ± 3.7 52.5 ± 3.0 0.29
HF, nu 47.2 ± 4.5 42.3 ± 3.7 47.5 ± 3.0 0.29
LF/HF 2.0 ± 0.3 2.3 ± 0.4 1.7 ± 0.2 0.12
BP variability
LFSBP, mmHg
2 8.2 ± 1 7.8 ± 1 6.4 ± 1 0.07
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Highlights 
• Non-invasive vagus nerve stimulation (tVNS) is investigated as a therapy for a 
range of conditions. 
• The mechanisms involved in positive outcomes of tVNS are not fully understood. 
• We show that tVNS improves spontaneous cardiac baroreflex sensitivity in healthy 
men. 
• These effects are specific to stimulation of auricular branch of the vagus nerve. 
